UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
Thrombosis and haemostasis, ISSN 0340-6245, 09/2015, Volume 113, Issue 5, pp. 931 - 942
Review Article | Rivaroxaban | Antidotes | Dabigatran | New anticoagulants | Apixaban | Peripheral Vascular Disease | Life Sciences & Biomedicine | Hematology | Cardiovascular System & Cardiology | Science & Technology | Recombinant Proteins - therapeutic use | Pyrazoles - therapeutic use | Anticoagulants - administration & dosage | Thrombosis - complications | Humans | Antibodies, Monoclonal - therapeutic use | Heparin - therapeutic use | Hemorrhage - prevention & control | Thiazoles - therapeutic use | Dabigatran - therapeutic use | Vitamin K - antagonists & inhibitors | Benzamides - therapeutic use | Anticoagulants - chemistry | Factor Xa - therapeutic use | Intracranial Hemorrhages - prevention & control | Rivaroxaban - therapeutic use | Pyridines - therapeutic use | Polysaccharides - therapeutic use | Hemostatics - chemistry | Antibodies, Monoclonal, Humanized - therapeutic use | Administration, Oral | Antithrombins - therapeutic use | Infusions, Parenteral | Clinical Trials as Topic | Factor Xa Inhibitors - therapeutic use | Animals | Protamines - therapeutic use | Pyridones - therapeutic use | Thrombosis - drug therapy | Hemorrhage - chemically induced | Hemostatics - therapeutic use
Journal Article
2.
Full Text
Discontinuation and Management of Direct-Acting Anticoagulants for Emergency Procedures
The American journal of emergency medicine, ISSN 0735-6757, 2016, Volume 34, Issue 11, pp. 14 - 18
Journal Article
3.
Full Text
Discontinuation and Management of Direct-Acting Anticoagulants for Emergency Procedures
The American journal of medicine, ISSN 0002-9343, 2016, Volume 129, Issue 11, pp. S47 - S53
Internal Medicine | Ciraparantag | DOAC reversal | Factor Xa inhibitor | Direct oral anticoagulant | Andexanet alfa | Idarucizumab | Emergency procedure | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Recombinant Proteins - therapeutic use | Pyrazoles - therapeutic use | Antibodies, Monoclonal, Humanized - therapeutic use | Surgical Procedures, Operative | Antithrombins - therapeutic use | Humans | Prothrombin Time | Emergencies | Anticoagulants - therapeutic use | Heparin - therapeutic use | Hemorrhage - prevention & control | Piperazines - therapeutic use | Heparin, Low-Molecular-Weight - therapeutic use | Arginine - analogs & derivatives | Dabigatran - therapeutic use | International Normalized Ratio | Factor Xa Inhibitors - therapeutic use | Deprescriptions | Pyridones - therapeutic use | Hemorrhage - chemically induced | Arginine - therapeutic use | Factor Xa - therapeutic use | Rivaroxaban - therapeutic use | Antidotes - therapeutic use | Periodical publishing | Medical colleges | Analysis | Monoclonal antibodies | Strategic planning (Business) | Anticoagulants (Medicine) | Pharmaceutical industry | Index Medicus | Abridged Index Medicus
Journal Article
The New England journal of medicine, ISSN 0028-4793, 12/2015, Volume 373, Issue 25, pp. 2413 - 2424
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Recombinant Proteins - therapeutic use | Pyrazoles - therapeutic use | Humans | Middle Aged | Male | Rivaroxaban - adverse effects | Female | Factor Xa - therapeutic use | Prothrombin - metabolism | Rivaroxaban - therapeutic use | Pyrazoles - adverse effects | Antidotes - pharmacology | Peptide Fragments - metabolism | Double-Blind Method | Administration, Oral | Recombinant Proteins - pharmacology | Factor Xa - metabolism | Protein Precursors - metabolism | Factor Xa Inhibitors - therapeutic use | Hemorrhage - drug therapy | Blood Coagulation - drug effects | Factor Xa - pharmacology | Factor Xa Inhibitors - adverse effects | Aged | Pyridones - therapeutic use | Hemorrhage - chemically induced | Pyridones - adverse effects | Antidotes - therapeutic use | Treatment outcome | Usage | Analysis | Clinical trials | Anticoagulants (Medicine) | Dosage and administration | Hemorrhage | Risk factors | Prevention | Anticoagulants | Side effects | Inhibitor drugs | Prothrombin | Thrombin | Thrombosis | Index Medicus | Abridged Index Medicus
Journal Article
Journal of thrombosis and haemostasis, ISSN 1538-7933, 03/2016, Volume 14, Issue 3, pp. 623 - 627
Peripheral Vascular Disease | Life Sciences & Biomedicine | Hematology | Cardiovascular System & Cardiology | Science & Technology | Recombinant Proteins - therapeutic use | Antibodies, Monoclonal, Humanized - therapeutic use | Anticoagulants - administration & dosage | Administration, Oral | Humans | Piperazines - therapeutic use | Anticoagulants - adverse effects | Arginine - analogs & derivatives | Coagulants - therapeutic use | Hemorrhage - drug therapy | Blood Coagulation - drug effects | Antidotes - adverse effects | Antidotes - pharmacokinetics | Coagulants - pharmacokinetics | Hemorrhage - chemically induced | Arginine - therapeutic use | Coagulants - adverse effects | Factor Xa - therapeutic use | Antidotes - therapeutic use | Usage | Anticoagulants (Medicine) | Index Medicus
Journal Article
Stroke (1970), ISSN 0039-2499, 09/2018, Volume 49, Issue 9, pp. 2237 - 2240
dabigatran | rivaroxaban | apixaban | humans | intracranial hemorrhages | Clinical Neurology | Peripheral Vascular Disease | Neurosciences & Neurology | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Pyrazoles - therapeutic use | Stroke - prevention & control | Antibodies, Monoclonal, Humanized - therapeutic use | Administration, Oral | Antithrombins - therapeutic use | Humans | Anticoagulants - therapeutic use | Stroke - drug therapy | Dabigatran - therapeutic use | Tissue Plasminogen Activator | Administration, Intravenous | Factor Xa Inhibitors - therapeutic use | Brain Ischemia - drug therapy | Fibrinolytic Agents - therapeutic use | Intracranial Hemorrhages - epidemiology | Pyridones - therapeutic use | Odds Ratio | Rivaroxaban - therapeutic use | Antidotes - therapeutic use | Practice Guidelines as Topic | Index Medicus
Journal Article
Gastrointestinal endoscopy, ISSN 0016-5107, 2012, Volume 76, Issue 1, pp. 18 - 24
Gastroenterology and Hepatology | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Gastroenterology. Liver. Pancreas. Abdomen | Biological and medical sciences | Medical sciences | Lactation | Humans | Digestive System Diseases - diagnosis | Naloxone - therapeutic use | Narcotics - therapeutic use | Hypnotics and Sedatives - therapeutic use | Endoscopy, Gastrointestinal - adverse effects | Cathartics - therapeutic use | Digestive System Diseases - therapy | Pregnancy | Anti-Bacterial Agents - therapeutic use | Narcotic Antagonists - therapeutic use | Female | Endoscopy, Gastrointestinal - methods | Benzodiazepines - therapeutic use | Antidotes - therapeutic use | Parasympatholytics - therapeutic use | Endoscopic surgery | Questions and answers | Endoscopy | Index Medicus
Journal Article
JOURNAL OF LARYNGOLOGY AND OTOLOGY, ISSN 0022-2151, 04/2020, Volume 134, Issue 4, pp. 316 - 322
Life Sciences & Biomedicine | Otorhinolaryngology | Science & Technology | Piperazines - administration & dosage | Recombinant Proteins - therapeutic use | Factor Xa - administration & dosage | Dabigatran - adverse effects | Prevalence | Awareness | Humans | Male | Antidotes - administration & dosage | Arginine - analogs & derivatives | Dabigatran - therapeutic use | Arginine - administration & dosage | Antibodies, Monoclonal, Humanized - administration & dosage | Rivaroxaban - adverse effects | Factor Xa - therapeutic use | Rivaroxaban - therapeutic use | Epistaxis - drug therapy | Severity of Illness Index | Antibodies, Monoclonal, Humanized - therapeutic use | Administration, Oral | Antithrombins - therapeutic use | First Aid - standards | Anticoagulants - therapeutic use | Epistaxis - chemically induced | Piperazines - therapeutic use | Anticoagulants - adverse effects | Recombinant Proteins - administration & dosage | Factor Xa Inhibitors - therapeutic use | Antithrombins - adverse effects | Epistaxis - epidemiology | Factor Xa Inhibitors - adverse effects | Aged | Arginine - therapeutic use | Antidotes - therapeutic use | Intervention | Anticoagulants | Cardiac arrhythmia | Embolization | Thromboembolism | Patients | Bleeding | Index Medicus | Abridged Index Medicus
Journal Article
Pharmacology & therapeutics (Oxford), ISSN 0163-7258, 2002, Volume 96, Issue 2, pp. 67 - 202
Heat shock proteins | Enzyme inhibition | Flavonoids | Benzopyrones | Gene expression | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Free Radical Scavengers - pharmacology | Electron Transport | Free Radical Scavengers - chemistry | Anti-Infective Agents - pharmacology | Humans | Isomerism | Anti-Ulcer Agents - pharmacology | Flavonoids - biosynthesis | Flavonoids - pharmacology | Antirheumatic Agents - pharmacology | Plant Physiological Phenomena | Chelating Agents - therapeutic use | Wound Healing - drug effects | Antirheumatic Agents - therapeutic use | Antidotes - pharmacology | Anti-Ulcer Agents - therapeutic use | Enzyme Inhibitors - pharmacology | Anti-Infective Agents - therapeutic use | Chelating Agents - pharmacology | Enzyme Inhibitors - therapeutic use | Cardiovascular Agents - pharmacology | Cardiovascular Agents - therapeutic use | Flavonoids - toxicity | Animals | Anticholesteremic Agents - therapeutic use | Flavonoids - chemistry | Anticholesteremic Agents - pharmacology | Antidotes - therapeutic use | Index Medicus
Journal Article